Analiza

Executive Summary

Analiza, Inc. is a US-based contract research organization (CRO) specializing in physicochemical property and in-vitro ADME screening for early-stage drug discovery. Founded in 2003 and headquartered in Cleveland, Ohio, the company provides fast, flexible, and affordable analytical services to pharmaceutical, biotechnology, and academic institutions. By utilizing gold-standard, miniaturized assays, Analiza aims to deliver high-quality data that accelerates therapeutic development. Operating within the diagnostics and proteomics sectors, the company serves as a critical partner for drug developers seeking to optimize lead compounds and reduce attrition in preclinical pipelines. Despite being a private company with limited public financial disclosures, Analiza's established presence and niche expertise position it as a reliable service provider in the competitive CRO landscape.

Upcoming Catalysts (preview)

• Q3 2026Launch of new high-throughput screening platform70% success
• Q4 2026Strategic partnership with a top-20 pharmaceutical company50% success
• Q1 2027Expansion into biologics characterization services60% success